Invasive Pneumococcal Disease Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Invasive Pneumococcal Disease Epidemiology Forecast Report Coverage

Expert Market Research's “Invasive Pneumococcal Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of invasive pneumococcal disease. It projects the future incidence and prevalence rates of invasive pneumococcal disease cases across various populations. The study covers age, gender, and type as major determinants of the invasive pneumococcal disease population. The report highlights patterns in the prevalence of invasive pneumococcal disease over time and projects future trends based on multiple variables.

Invasive Pneumococcal Disease Understanding: Disease Overview

Invasive Pneumococcal Disease (IPD) is a severe bacterial infection caused by Streptococcus pneumoniae, occurring when the bacteria invade normally sterile body sites such as blood, cerebrospinal fluid, or joints. Manifestations include bacteremia, meningitis, septicemia, and, less commonly, osteomyelitis. IPD predominantly affects infants, young children, older adults, and individuals with immunocompromising conditions. Despite global vaccination efforts, IPD remains a significant cause of morbidity and mortality worldwide. Early recognition of symptoms, understanding regional serotype prevalence, and prompt diagnosis are critical for effective disease management and prevention.

Invasive Pneumococcal Disease Epidemiology Perspective

The invasive pneumococcal disease epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Invasive Pneumococcal Disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for invasive pneumococcal disease and their trends. The invasive pneumococcal disease detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Pneumococcal infections caused approximately 179,354 deaths among individuals aged <20 years globally in 2021, with the highest burden in children under 5.
• These infections accounted for around 15,757,828 disability‑adjusted life years (DALYs) in the same age group, reflecting substantial health loss.
• Children under 5 years experienced the highest age‑standardized mortality and DALY rates, significantly greater than older age groups.
• Mortality and DALYs were higher in males than females globally among the <20 age cohort.
• Pneumococcal meningitis, a severe invasive infection, primarily affects infants and older adults. Incidence ranges around 1-1.5 per 100,000 population, with Streptococcus pneumoniae remaining a leading bacterial cause globally.
• Disease incidence and mortality remain highest in developing regions of Africa and Asia, driven by high pneumonia rates and lower vaccination coverage compared with high‑income countries.

Read more about this report - Request a Free Sample

Country-wise Invasive Pneumococcal Disease Epidemiology Segment

The invasive pneumococcal disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Invasive Pneumococcal Disease (IPD) remains a serious global health concern, particularly in young children and older adults. In the United States, surveillance reports an overall incidence of 8.3 cases per 100,000 population, with infants under 1 year and adults ≥65 years most affected. In the United Kingdom, 4,598 laboratory-confirmed IPD cases were recorded in 2022-23, following 3,025 in 2021-22 and 1,240 in 2020-21. Males show slightly higher incidence than females, and vaccine-targeted serotypes like 3, 19A, and 19F continue to dominate.

Invasive Pneumococcal Disease: Treatment Overview

Treatment of IPD relies on prompt administration of appropriate antibiotics, with choices guided by local resistance patterns. Penicillin, ceftriaxone, or vancomycin are commonly used for severe infections, while supportive care addresses complications like sepsis or meningitis. Prevention through pneumococcal conjugate (PCV) and polysaccharide (PPSV) vaccines is central to reducing incidence. Adjunctive strategies include corticosteroids for severe meningitis cases and intensive care support when needed. Timely vaccination, early diagnosis, and evidence-based antimicrobial therapy are critical to improving outcomes and minimizing mortality in high-risk populations.

Key Questions Answered

• What are the key findings of invasive pneumococcal disease epidemiology in the 8 major markets?
• What will be the total number of patients with invasive pneumococcal disease across the 8 major markets during the forecast period?
• What was the country-wise invasive pneumococcal disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of invasive pneumococcal disease during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of invasive pneumococcal disease during the forecast period of 2026-2035?
• What are the currently available treatments for invasive pneumococcal disease?
• What are the disease risks, signs, symptoms, and unmet needs of invasive pneumococcal disease?

Scope of the Invasive Pneumococcal Disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of invasive pneumococcal disease based on several factors.
• Invasive Pneumococcal Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The invasive pneumococcal disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Pneumococcal Vaccine Market

Pneumococcal Infections Drug Pipeline Analysis

Pneumococcal Disease Drug Pipeline Analysis